# Simufilam PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/simufilam

> Simufilam, sponsored by FILANA THERAPEUTICS, INC. (FLNA): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | simufilam |
| Codes | PTI-125 |
| Sponsor | FILANA THERAPEUTICS, INC. (FLNA) https://sec-api.dev/companies/flna/catalysts |
| Indications | [mild-to-moderate alzheimer's disease](https://sec-api.dev/indications/mild-to-moderate-alzheimer-s-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### November 25, 2024: topline data readout

- Status: completed, missed. Date confidence: exact. Stage: 3.
- First seen 2024-11-25, last confirmed 2025-11-12.
- SEC Form 10-K (accession 0001437749-25-005919): "On November 25, 2024, we announced that the top-line results from the Phase 3 RETHINK-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." https://www.sec.gov/Archives/edgar/data/1069530/000143774925005919/sava20241231c_10k.htm
- SEC Form 10-K (accession 0001437749-25-005919): "For example, on November 25, 2024, we announced that the topline results from our Phase 3 RETHINK-ALZ study of simufilam in Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." https://www.sec.gov/Archives/edgar/data/1069530/000143774925005919/sava20241231c_10k.htm
- SEC Form 8-K (accession 0001171843-25-000089): "On November 25, 2024, the Company reported that the topline results from its Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet its prespecified co-primary endpoints and announced the Company's decision to discontinue its Phase 3 ReFocus-ALZ study and its open label extension study." https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/f8k_010725.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-24-006545): "AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer's disease (AD) dementia, today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." https://www.sec.gov/Archives/edgar/data/1069530/000117184324006545/exh_991.htm
- SEC Form 10-Q (accession 0001437749-25-034427): "On November 25, 2024, we announced that the top-line results from the Phase 3 RETHINK-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." https://www.sec.gov/Archives/edgar/data/1069530/000143774925034427/sava20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-026686): "On November 25, 2024, we announced that the top-line results from the Phase 3 RETHINK-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." https://www.sec.gov/Archives/edgar/data/1069530/000143774925026686/sava20250630_10q.htm
- SEC Form 10-Q (accession 0001437749-25-015478): "On November 25, 2024, we announced that the top-line results from the Phase 3 RETHINK-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." https://www.sec.gov/Archives/edgar/data/1069530/000143774925015478/sava20250331_10q.htm

### March 25, 2025: topline data readout

- Status: completed, missed. Date confidence: exact. Stage: 3. Indication: mild-to-moderate Alzheimer's disease.
- First seen 2025-01-07, last confirmed 2025-11-12.
- SEC Form 8-K (accession 0001171843-25-001678): "On March 25, 2025, the Company announced that the topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." https://www.sec.gov/Archives/edgar/data/1069530/000117184325001678/f8k_032525.htm
- SEC Form 10-Q (accession 0001437749-25-034427): "On March 25, 2025, we announced that top-line results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." https://www.sec.gov/Archives/edgar/data/1069530/000143774925034427/sava20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-026686): "On March 25, 2025, we announced that top-line results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." https://www.sec.gov/Archives/edgar/data/1069530/000143774925026686/sava20250630_10q.htm
- SEC Form 10-Q (accession 0001437749-25-015478): "On March 25, 2025, we announced that top-line results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer's disease did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints." https://www.sec.gov/Archives/edgar/data/1069530/000143774925015478/sava20250331_10q.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001183): "Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer's disease, expected late first-quarter/early second-quarter 2025" https://www.sec.gov/Archives/edgar/data/1069530/000117184325001183/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000089): "Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease expected late first-quarter/early second-quarter 2025" https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/exh_991.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-01-07, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001183): "Topline data for the study are anticipated in late first-quarter/early second-quarter 2025." https://www.sec.gov/Archives/edgar/data/1069530/000117184325001183/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000089): "We are in the final stages of discontinuing the REFOCUS-ALZ study and expect to report topline results late first-quarter/early second-quarter 2025." https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000089): "The Company expects to report topline data for this study late first-quarter/early second-quarter 2025." https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/exh_991.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000089): "The Company is on track to complete these efforts and plans to release top-line REFOCUS-ALZ results late first-quarter/early second-quarter 2025." https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/exh_991.htm
- SEC Form 10-Q (accession 0001437749-25-015478): "Following the release of the topline RETHINK-ALZ and REFOCUS-ALZ results, the Company announced the decision to phase out the Company's Alzheimer's disease development program, which we expect to be completed by the end of the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1069530/000143774925015478/sava20250331_10q.htm

## Same indication

- [ZUNVEYL (benzgalantamine)](https://sec-api.dev/pdufa/benzgalantamine) (ACOG)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/simufilam.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Simufilam PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/simufilam

```bibtex
@misc{secapidev_pdufa_simufilam_20261116,
  title        = {Simufilam PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/simufilam}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_simufilam_20261116","title":"Simufilam PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/simufilam","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
